Interview: Galapagos Pipeline In Good Shape
Following more promising rheumatoid arthritis data on filgotinib at EULAR, the Belgian biotech's chief medical officer Walid Abi-Saab tells Scrip about the JAK inhibitor's promise in a number of other indications.
You may also be interested in...
With data showing the superiority of its JAK inhibitor over Humira, the US firm is looking beyond treating the symptoms of rheumatoid arthritis to achieving remission.
Belgium’s Galapagos adds another potential fibrosis drug to its growing pipeline of compounds in a therapeutic area that is also attracting attention from a number of other companies.
The French drugmaker's current product portfolio is performing well but a €669m charge relating to the failure of palovarotene for the rare bone disease FOP blighted Ipsen's financials.